Brief: Sequana Medical H1 EBIT Loss Widens To 13.3 Mln

Sequana Medical NV

08/09/2022 06:04

Sept 8 (Reuters) - SEQUANA MEDICAL NV  SEQUA.BR :
    * SEQUANA MEDICAL ANNOUNCES H1 2022 RESULTS AND PROVIDES
BUSINESS
UPDATE
    * TOTAL LIQUIDITY POSITION OFEUR 23.8 MILLION AND CASH
RUNWAY INTO
Q3 2023
    * REVENUE INCREASED FROM EUR 0.02 MILLION IN H1 2021 TO EUR
0.46
MILLION IN H1 2022
    * EARNINGS BEFORE INTEREST AND TAXES (EBIT) EVOLVED FROM A
LOSS OF
EUR 11.48 MILLION IN H1 2021 TO A LOSS OF EUR 13.29 MILLION IN
H1 2022
    * NET LOSS INCREASED FROM EUR 11.89 MILLION IN H1 2021 TO
EUR
14.86 MILLION IN H1 2022
    * NET DEBT AT 30 JUNE 2022 IMPROVED BY EUR 13.63 MILLION
COMPARED
TO 31 DECEMBER 2021
    * DSR - CLINICAL EVIDENCE OF DISEASE-MODIFYING HEART FAILURE
DRUG
THERAPY/PREPARATIONS ONGOING TO START US PHASE 1B/2A MOJAVE
STUDY IN H1 2023
    * ALFAPUMP - STRONG INTERIM DATA / ON TRACK TO REPORT
PRIMARY
ENDPOINT DATA OF NORTH AMERICAN PIVOTAL POSEIDON STUDY IN Q4
2022

Source text for Eikon:  ID:nGNXb8mJN 
Further company coverage:  SEQUA.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 587 696 600;))